Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954386 | 0.86 | ALDH1A1 (0.47) | ALDH1A1TP53KMT2ARAB9ANPC1 | |
| SCHEMBL2958606 | 0.85 | POLB (0.46) | ALDH1A1TP53KMT2ANQO1RAB9A | |
| SCHEMBL2956519 | 0.85 | KMT2A (0.45) | ALDH1A1TP53KMT2ANQO1RAB9A | |
| SCHEMBL2966016 | 0.76 | ALDH1A1 (0.47) | ALDH1A1TP53KMT2ARAB9APOLB | |
| SCHEMBL2965451 | 0.74 | SMN1; SMN2 (0.50) | ALDH1A1TP53KMT2ANQO1RAB9A | |
| SCHEMBL2956897 | 0.74 | TSHR (0.57) | ALDH1A1KMT2ANQO1RAB9APOLB | |
| SCHEMBL2954335 | 0.73 | GABRP (0.50) | ALDH1A1KMT2ARAB9APOLBNPC1 | |
| SCHEMBL2960499 | 0.73 | CYP3A4 (0.48) | ALDH1A1TP53KMT2ANQO1RAB9A | |
| SCHEMBL11269213 | 0.72 | SMN1; SMN2 (0.57) | ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL2961210 | 0.71 | NQO1 (0.45) | KMT2ANQO1CYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772237-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2009-04-23 | — | — | US | disclosed |
| US-7476690-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2009-01-13 | — | — | US | disclosed |
| EP-1735300-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-26 | — | — | US | disclosed |
| US-7119214-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-12-22 | — | — | US | disclosed |
| WO-2005100345-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1589016-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | ALDH1A1 2457/4885TP53 2926/4885KMT2A 1455/4885 |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | ALDH1A1 2457/4885TP53 2926/4885KMT2A 1455/4885 |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | HTR1A, HTR2A, HTR5A | ALDH1A1 2457/4885TP53 2926/4885KMT2A 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.